Year-end valuation pressure: assumption changes, a solvency target and a distributor incentive not in the basis

There are six distinct issues, and they are not of equal weight.

1. Assumptions chosen to produce a result. Actuarial assumptions must be the actuary's independent best estimate (or prudent estimate, where the basis requires prudence), supported by evidence, and documented. They may not be selected because they deliver ₹85 crore. The fact that each figure lies within the model's range is irrelevant: three assumptions simultaneously at the aggressive end is a directional choice, not three coincidences.

2. Expense inflation cut from 6.0% to 4.5%. If actual cost inflation is running near 6%, this understates future maintenance expenses and overstates surplus.

3. Lapse assumption raised from 12% to 18% against 9% experience. This is the most serious of the three, because it moves in the opposite direction to the evidence. Higher lapse assumptions reduce reserves and flatter surplus. Doing it deliberately to hit a solvency target is mis-stating the balance sheet.

4. Longevity loading halved. Reducing the improvement loading understates annuity liabilities, which is exactly the kind of change that looks small at the year-end and is very expensive ten years later.

5. Early recognition of the ₹12 crore reinsurance profit commission. Accounting follows the treaty period, not the reporting need. Recognising it a year early is an accounting misstatement dressed as a timing judgment.

6. 'The board will remember who helped.' This is an inducement, and it converts a technical disagreement into an independence issue. The standards that apply are independence and objectivity, integrity, professional competence and due care, confidentiality, and professional behaviour. I should also treat the missing persistency and commission facts as a professional failure, not a favour to the CFO - if those facts are material and I sign without updating the basis, the deficiency is mine.

Day 1–2

• Ask the CFO to put the request in writing, with the desired output and the reason. A verbal request that would misstate the balance sheet should be made in writing; the request itself changes when it has to be written down.
• Do not agree, do not refuse in a corridor, and do not modify the model yet.

Day 3–7

• Test each assumption against evidence: expense experience for the last three years, lapse experience by duration and channel, and the latest mortality and longevity projections.
• Document the outcome for each: supported, unsupported, or needing a range with a recommended point.
• Write a short memo to the CFO: what the evidence supports, what the change would do to the technical provisions, and what you will sign.

Day 8–12

• Escalate to the Audit Committee and the Risk Committee, copying the CEO. Set out the disagreement, the financial effect, and the fact that the solvency ratio improvement is not a real improvement in capital.
• If the board persists, insist that the valuation report discloses the basis actually used, the alternative proposed and the fact that the actuary did not support it. An actuary can be overruled on a decision; he cannot be overruled on disclosure.

Day 13–20

• Revise the basis on the evidence: raise the lapse assumption only if experience supports it, adjust expense inflation to observed cost trends, and review longevity against the latest projections.
• Check whether the ₹85 crore disappears once the evidence is used. It almost certainly does.

Ongoing

• If the pressure continues after written escalation, consider notifying the regulator of matters that threaten the insurer's solvency or the integrity of its reporting, and consider resignation. Remember that a duty to report can survive resignation.
• Keep a contemporaneous file of requests, tests, memos and minutes. Assume it will be read by an independent reviewer.

Effect on the valuation. A 42% first-year commission with nothing thereafter is an incentive to sell, not to retain. Thirteen-month persistency of 58% against a valuation lapse assumption of 12% means the actual first-year lapse rate is around 42% - a gap of thirty points between assumption and experience. That gap has three consequences:

1. The lapse assumption is wrong, and the wrongness is in a direction that flatters the balance sheet.
2. Future new-business volumes and expense recovery are overstated. Acquisition costs are recovered over the life of a policy; if half the policies lapse in year one, the unamortised acquisition cost is a loss, not an asset.
3. The distribution cost structure is mispriced. A 42% first-year commission cannot be supported by a book that lapses at 42% in year one.

What I do. Do not sign a basis that contradicts experience I now know about. Re-run the valuation with the observed lapse rates by channel, and with the actual commission scale. Write the revised numbers and the reason for the change into the valuation report. If the revised basis reduces the solvency ratio below the control level, that is the finding - and it must go to the board and, where the rules require it, to the regulator. A solvency ratio that only survives because the actuary was kept in the dark is not a solvency ratio.

On being kept in the dark. Ask the Head of Compliance for the figures in writing and for the date she first knew them. Establish who else knew. It is a governance failure that the actuary's basis was not updated for published persistency and commission data; add that to the escalation memo. Do not treat the compliance officer's information as confidential gossip - it is valuation evidence, and you have a professional duty to act on it.